The Medium: The Rising Tide of Scientific Innovation: Biotech in 2020 and Beyond
Alzheimer’s Disease is notoriously difficult to detect and monitoring the progression of the disease is an invasive and costly affair, requiring extended hospital stays and procedures that present elevated costs to both patients and hospitals. C2N’s novel diagnostic is a blood test that measures levels of amyloid plaque to extrapolate the presence of neurodegenerative disease.